Company Profile

Expesicor Inc (AKA: Expesicor LLC)
Profile last edited on: 6/1/20      CAGE: 7Z6M3      UEI: N3JFHBMSK2D5

Business Identifier: Epilepsy and neurodegenerative disorders
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

350 North Meridian Road Box 10205
Kalispell, MT 59901
   (406) 668-1491
Location: Single
Congr. District: 01
County: Flathead

Public Profile

Addressing development of treatments for various neurological disorders and move them toward clinical trials and eventual commercialization, Expesicor Inc. is working with the University of Montana. With candidate treatments in the pipeline at various stages of development. the research effort is addressing Alzheimer’s, epilepsy, ALS and traumatic brain injury to include better ways both to detect and to understand such disorders. The firm has developed a drug (EXP-1602) that has cleared by the Food and Drug Administration to begin clinical trials. Expesicor is also working on further develop an imaging agent to identify pain in a patient, specifically using an imaging agent designed to visualize where an individual is experiencing pain providing a more objective pain measurement tool

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 1 NIH $343,042
Project Title: Modeling Drug-Refractory Epilepsy with the KAL Methodâ„
2019 1 NIH $407,654
Project Title: Developing EXP-1801 as an Imaging Agent to Quantify Pain and Analgesia

Key People / Management

  Braxton Norwood